Loading stock data…
PNTG
$31.30-0.02 (-0.06%)
Market ClosedLast close May 1
The Pennant Group, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Pennant Group, Inc. in the Healthcare sector is trading at $31.30. The stock is currently 11% below its 52-week high of $35.00, remaining 12.8% above its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why PNTG maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$31.30
Potential Downside
43.9%
Whystock Fair Value$17.56
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
34.96
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.06%
Volume
Today's trading volume
170,237
Recent News
Truist Sees Continued Upside for The Pennant Group, Inc. (PNTG) on Stable Demand Trends
We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. The Pennant Group, Inc. is one of the best healthcare stocks. TheFly reported on April 13 that Truist Financial analyst David MacDonald increased the price target for The PNTG to $36 from $34 and maintained a Buy […]
3 Profitable Stocks That Fall Short
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
5 Low-Leverage Stocks to Buy as Investors Hope for Truce
Low-leverage stocks like PNTG gain appeal as investors seek stability amid geopolitical tensions, with strong earnings growth and strategic moves boosting outlook.
Winners And Losers Of Q4: The Pennant Group (NASDAQ:PNTG) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks
Looking back on senior health, home health & hospice stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including The Pennant Group (NASDAQ:PNTG) and its peers.
Why The Pennant Group (PNTG) Story Is Shifting As Analysts Rework Targets And Guidance
Analysts are keeping Pennant Group’s modelled fair value anchored at US$37.83 while lifting individual price targets into the high US$30s to low US$40s range. This mix of a steady valuation anchor and higher targets reflects optimism about long term earnings from the AMED assets, balanced against caution around execution and 2026 guidance. Read on to see what these shifting targets mean for you and how to track the evolving analyst narrative around Pennant. Stay updated as the Fair Value for...